Press "Enter" to skip to content

AstraZeneca’s Imfinzi fails to meet main goals in head and neck cancer study

The study, known as "EAGLE", did not improve overall survival compared with standard chemotherapy in patients with the hard-to-treat disease, the company said.

Original source:

Also Read:   Morphosys CFO says tafasitamab drug sales potential above $1 billion: magazine